Zeleciment Rostudirsen not checked
Dyne Therapeutics · DYNE-251
FollowEvery change as it happens, and a Monday email
Trials
2 active
2 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Duchenne Muscular Dystrophy (DMD) (2 trials), Muscular Dystrophy, Duchenne, Muscular Dystrophy (DMD), DMD, Muscular Dystrophies, Muscular Dystrophy in Children, Muscular Dystrophy, Duchenne Type, Muscular Dystrophy, Duchenne and Becker Types and 5 more
- Main trialPhase 3
- “The purpose of the study is to assess the efficacy, safety, and tolerability of zeleciment rostudirsen (DYNE-251) administered intravenously (IV) every 4 weeks to ambulatory Duchenne muscular dystrophy (DMD) participants, 4 to 18 years of age, with dystrophin mutations amenable to exon 51 skipping.”In the company’s words, NCT07608432 on ClinicalTrials.gov
- Other names
- DYNE-251
Other drugs for Duchenne Muscular Dystrophy (DMD)
- AOC 1044Avidity Biosciences, Inc. · Phase 3
- Givinostat HydrochlorideItalfarmaco · Phase 3
- SGT-003Solid Biosciences Inc. · Phase 3
- DeramiocelCapricor Inc. · Phase 3
- SatralizumabRoche · Phase 2
- DS-5141bDaiichi Sankyo · Phase 2
Coming up2
- Dec 2030Phase 3 trial completes · ClinicalTrials.gov
- Sep 2031Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Dec 2030 | Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO) | |
| Phase 1/2Active, not recruiting | Sep 2031 | Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026